Table 3.
Demographic, clinical characteristics, and laboratory findings of nonsurvivors and survivors in critically ill patients.
| Non-survivors n = 56 |
Survivors n = 20 |
p Value | |
|---|---|---|---|
| Demographic | |||
| Age (year) | 65.4 ± 7.7 | 62.0 ± 12.7 | 0.274 |
| Male, n (%) | 38 (67.9 %) | 11 (55 %) | 0.302 |
| Clinical characteristics | |||
| APACHEII | 14 (10–20) | 11 (9.25–13.0) | 0.021 |
| SOFA | 6 (4–8.75) | 4 (3–5) | 0.002 |
| Invasive ventilation | 50 (89.3 %) | 10 (50 %) | 0.002 |
| Glucocorticoids | 48 (85.7 %) | 15 (75 %) | 0.739 |
| Vasopressors | 44 (78.6 %) | 4 (20 %) | <0.001 |
| Death, n (%) | 56 (100 %) | 0 | |
| Disease course | 26 (20–35) | 35.5 (27–49) | 0.016 |
| Time of hospitalization (days) | 13.5 (9–23) | 16 (8.25–22) | 0.007 |
| Time of ICU (days) | 8.5 (5–13) | 14 (7–27) | 0.015 |
| Comorbidity | |||
| Hypertension | 19 (33.9 %) | 16 (80 %) | <0.001 |
| Diabetes mellitus | 11 (19.6 %) | 7 (35 %) | 0.280 |
| Coronary heart disease | 11 (19.6 %) | 5 (25 %) | 0.853 |
| Current smoker | 8 (14.3 %) | 3 (15 %) | 0.992 |
| Cerebrovascular disease | 1 (1.8 %) | 4 (20 %) | 0.016 |
| Laboratory findings | |||
| White blood cell count (×109/L) | 12.11 (9.23–18.86) | 9.32 (6.25–12.7) | 0.017 |
| Neutrophil count (×109/L) | 10.94 (8.11–17.27) | 8.38 (5.05–11.08) | 0.017 |
| Lymphocytes (×109/L) | 0.53 (0.38–0.73) | 0.65 (0.41–0.83) | 0.243 |
| Hemoglobin (g/L) | 126 (109–140) | 114 (93.75–133.25) | 0.115 |
| Platelets (×109/L) | 157 (77–217) | 181 (134.5–270.8) | 0.075 |
| Serum albumin (g/L) | 27.75 (25.08–31.23) | 30.40 (28.1–33.1) | 0.035 |
| Serum calcium (mmol/L) (2.15–2.50) | 2.21 (.95–2.31) | 2.07 (1.91–2.20) | 0.115 |
| Serum inorganic phosphorus (mmol/L) (0.81–1.45) | 0.99 (0.78–1.15) | 0.98 (0.86–1.37) | 0.591 |
| Serum uric acid (mmol/L) (142.8–339.2) | 214.0 (134.0–302.8) | 214.0 (161.3–334.8) | 0.483 |
| Urea (mmol/L) (2.6–7.5) | 8.25 (5.43–11.0) | 8.80 (6.05–15.15) | 0.286 |
| sCr (umol/L) | 78.5 (54.75–111.25) | 74.0 (45.75–90.75) | 0.190 |
| Elevated sCr, n (%) | 15 (26.8 %) | 4 (20 %) | 0.547 |
| Declined sCr, n (%) | 6 (10.7 %) | 7 (35 %) | 0.033 |
| eGFR-Cr (ml/min/1.73m2) | 85.85 (55.78–98.0) | 84.85(70.85–107.85) | 0.392 |
| eGFR-Cr<60 | 16 (28.6 %) | 5 (15 %) | 0.229 |
| CysC (mg/L) | 1.21 (0.95–1.83) | 1.13 (1.05–1.50) | 0.972 |
| Elevated CysC, n (%) | 20 (35.7 %) | 4 (20 %) | 0.194 |
| Declined CysC, n (%) | 0 | 0 | |
| eGFR-CysC (ml/min/1.73m2) | 57.51 (30.51–81.54) | 60.86 (43.55–67.96) | 0.972 |
| eGFRcr-cysc (ml/min/1.73m2) | 68.69 (41.72–91.23) | 74.70 (57.66–89.63) | 0.663 |
| eGFRcr-cysc<60 | 24 (42.9 %) | 5 (25 %) | 0.158 |
| IL-6 (pg/ml) | 116.5 (37.15–220.4) | 29.76 (19.16–38.38) | <0.001 |
| IL-8 (pg/ml) (<62) | 29.65 (15.30–63.85) | 22.9 (9.55–31.25) | 0.045 |
| IL-10 (pg/ml) (<9.1) | 13.5 (7.9–20.3) | 7.8 (6.05–12.45) | 0.057 |
| TNF-α (pg/ml) (<8.1) | 10.55 (7.18–19.35) | 9.8 (6.95–13.8) | 0.459 |
| Ferritin (mg/ml) | 1427.1 (829.15–2483.15) | 867.7 (649.7–1852.5) | 0.057 |
| D-dimer (mg/ml FEU), n (%) | 0 | 0 | |
| 0.5–5.0 | 16 (28.6 %) | 12 (60 %) | |
| 5.0–21.0 | 12 (21.4 %) | 3 (15 %) | 0.048 |
| >21.0 | 27 (48.2 %) | 5 (25 %) | |
| hsCRP (mg/L) | 110.20 (64.53–162.55) | 60.25 (31.43–117.35) | 0.009 |
APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment.